Key Drivers
- High margins
- Modest leverage
- Unsustainable payout
AIAI Summary
QGEN's strategic shift from a consumables cash engine toward capital‑intensive platform rollouts (QIAstat‑Rise, Parse, digital bioinformatics) means future upside now hinges on execution of commercial rollouts and M&A integration rather than steady instrument cycles — so the key actionable monitor is consistent FCF coverage of the >100% payout and clear consumable attach rates from new platforms. If quarterly FCF sustains covering dividends without more leverage and instrument‑to‑consumable conversion visibly accelerates, the stock re‑rates; if not, expect dividend pressure, impairment risk, and further downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Modest leverage
- •Unsustainable payout
QGEN combines strong profitability and cash generation with healthy liquidity but faces dividend sustainability and intangible-asset quality risks.
Price Behavior
Key Price Behavior Insights:
- •Rapid decline
- •Established support
- •High volatility
QGEN fell roughly 17–18% last month from $48.57 to $39.93, establishing a near‑term support at $39.93 (with a low‑$40 cluster around $40.60–$41.21) but facing resistance in the $48.50–$50.40 area and around $43.00, leaving it in a short‑term downtrend with elevated volatility and risk of further downside if $39.93 fails.
17–18% drop from $48.57 to $39.93 over last month indicating rapid sell‑off and elevated volatility
Sentiment & News
Key News Insights:
- •Regulatory expansion
- •TB clinical data
- •Mixed investors
Qiagen secured FDA clearance expanding QIAstat-Dx Rise GI testing, published supportive QuantiFERON‑TB data, filed its 20‑F and held investor engagement amid mixed ownership moves and cautious analyst sentiment.
These developments strengthen Qiagen's commercial and clinical credibility but are unlikely to reverse near‑term stock pressure given mixed investor flows and Hold analyst consensus
Similar Companies in Healthcare
Other companies in the same sector with AI ratings